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Bovine leukemia virus (BLV) is the causative agent of enzootic bovine leucosis, which results in 2 
significant economic losses on many affected farms. BLV infects a wide range of animals as well as cell 3 
lines derived from various mammalian species and organs; however, studies show that only some cell lines 4 
support sustained production of viral progeny. The differences between cells that produce viral progeny and 5 
those that do not are unclear. The aim of this study was to identify the steps of BLV replication that are 6 
associated with the capacity of a cell to support a productive infection. Eleven cell lines derived from 7 
various species were categorized into two groups, those that produce BLV progeny and those that do not, 8 
and the efficiency of viral attachment was compared. In addition, viral entry and reverse transcription were 9 
compared for two BLV-producing cell lines and three non-producing cell lines. BLV attached to and entered 10 
all of the tested cells. However, synthesis of viral DNA was inhibited in all three non-virus-producing cell 11 
lines, suggesting that BLV production was blocked either prior to or at the stage of reverse transcription. 12 
These results increase our understanding of the BLV life cycle and should enable better control over the 13 






Bovine leukemia virus (BLV) is a delta retrovirus that is closely related to human T cell leukemia 2 
virus (HTLV). About 30% of BLV-infected cattle show persistent lymphocytosis (PL), and some develop a 3 
B cell lymphoma called enzootic bovine leukemia (EBL) 5–10 years after infection. Although EBL occurs 4 
in less than 5% of infected cattle, infected asymptomatic cattle and cattle with PL also cause economic 5 
losses for affected farms [1, 2].  6 
The natural host of BLV is the cow; however, antibodies against BLV have been detected in domestic 7 
animals such as sheep, water buffalo, and alpaca [3, 4]. Recently, the possibility of BLV infection in humans 8 
[5], and an association between BLV and human breast cancer, has been suggested [6–10], although it is 9 
unclear how much BLV contributes to cancer in humans [11, 12]. Furthermore, various experimentally 10 
infected mammalian species and chickens show seroconversion [3, 13–17].  11 
The host range of BLV has also been studied using cell lines. These studies showed a wide range of 12 
BLV infection [18–20]. By contrast, a study of wild-type BLV revealed sustained production of progeny 13 
virus only in bat lung cells and canine thymus cells [18]. These results suggest that infection can proceed 14 
up to a certain point in a variety of cells, but that BLV can complete the replication cycle only in some host 15 
cells. It is not clear which steps of the BLV replication cycle are inhibited in non-permissive cells. Although 16 
elements of BLV infection and replication are being studied, the receptors and many other cellular factors 17 
involved in BLV infection and replication remain unclear [21–23].  18 
This study examined the capacity of cells derived from various mammalian species to produce 19 
progeny virus. The efficiency of early steps of BLV infection (i.e., BLV attachment, BLV entry, and viral 20 
cDNA synthesis) was compared in each cell type. We found that synthesis of viral cDNA was inhibited in 21 





Materials and Methods 1 
Cells and viruses 2 
MDBK cells [bovine kidney; American Type Culture Collection (ATCC) CRL6071] were purchased 3 
from RIKEN Bio Resource Center. SIRC cells (rabbit) [24] were kindly provided by Dr. A. Takase (SOKA 4 
University, Japan). BT (bovine turbinate; ATCC CRL-1390), EBTr (bovine trachea; ATCC CCL-44), 5 
NIH3T3 (mouse embryonic fibroblast; ATCC CRL-1658), SC-1 (mouse embryonic fibroblast; ATCC CRL-6 
1404), NRK (rat kidney; ATCC CRL-6509), Tb1Lu (bat; ATCC CCL-88), CC81 (cat) [25], COS7 (monkey 7 
kidney; ATCC CRL-1651), HOS (human bone; ATCC CRL-1543), and FLK-BLV (fetal lamb kidney cells 8 
persistently infected with BLV) [26] cells were maintained at our institute. BT cells were cultured in 9 
Dulbecco’s modified Eagle’s medium (DMEM) with high glucose (Sigma Aldrich) containing 10% fetal 10 
bovine serum (FBS), and all other cells were cultured in original DMEM (Thermo Fisher Scientific) 11 
containing 5% FBS at 37°C in 5% CO2.  12 
To obtain infectious BLV, FLK-BLV cells were cultured to 50–70% confluency in 10 cm dishes. The 13 
medium was then exchanged for 8 ml of fresh culture medium, and the culture fluid was collected after 16–14 
24 h. The culture supernatant was then passed through a 0.22 µm membrane to remove cell debris and used 15 
as a source of infectious BLV. BLV titers were measured using the syncytium formation method. To obtain 16 
high titer virus, fresh supernatants of FLK-BLV without freezing or thawing (1.3-1.6 ×104 syncytium 17 
formation units/ml) were used for the detection of BLV produced by cells (see below). For other 18 
experiments, BLV stocks with 1.4-1.6×103 syncytium formation units/ml were used.  19 
 20 
Detection of BLV produced by cells 21 
On the day before infection, 1×105 cells were seeded into 6 well plates. The next day, medium was 22 
replaced with culture medium containing polybrene (final concentration, 10 µg/ml) in order to increase the 23 
infection efficiency. After 1 h, the medium was replaced with FLK-BLV cell culture supernatant or normal 24 
culture medium containing 10 µg/ml polybrene (Millipore). After 1 h, the medium was removed and the 25 
cells were cultured for an additional 7 days in fresh culture medium containing 10% FBS. Cells were 26 
passaged at about a 1:4 ratio when confluent. Seven days after virus inoculation, the culture fluid was 27 
collected, passed through a 0.22 µm membrane, and used for the NIH3T3 cell-binding assay or for the 28 
syncytium formation assay using CC81 cells (see below) [25].  29 
For the syncytium formation assay, CC81 cells were seeded in 3.5 cm dishes at a density of 5×104 30 
cells/dish. The next day, the cells were pre-incubated for 1 h with medium containing 20 µg/ml polybrene, 31 
which was subsequently replaced with culture fluid from various BLV-infected cells containing 20 µg/ml 32 




incubated for 4 days. Cells were then fixed with methanol and stained with May-Grunwald-Giemsa reagent 1 
(1:20 dilution in deionized water) (Wako). The dishes were divided into squares and the number of 2 
multinucleated cells per square was counted. 3 
 4 
Detection of BLV attached to the cell surface  5 
Cells were detached from culture dishes using Hank’s buffer containing 0.05% trypsin and 0.2 g/L 6 
EDTA-4Na (Thermo Fisher Scientific), followed by washing first with DMEM containing 10% FBS and 7 
then with ice-cold DMEM containing 1% FBS and 0.05% NaN3 (FACS buffer). All subsequent washes 8 
were performed with ice-cold FACS buffer, and for all centrifugation steps, cells were spun for 2 min at 9 
600 × g at 4°C. Cells (6×105) were suspended in 1 ml of ice-cold culture supernatant from FLK-BLV cells 10 
and incubated for 1 h at 4°C with mild shaking. After two washes, the cells were incubated for 30 min on 11 
ice with a mouse anti-BLV envelope glycoprotein gp51 monoclonal antibody (BLV2; 1:100 dilution in 12 
FACS buffer) (VMRD). The cells were then washed twice and incubated for 30 min on ice with a 13 
biotinylated anti-mouse IgG antibody (1:100 dilution in FACS buffer) (Jackson Laboratories), followed by 14 
two washes and a final incubation for 30 min on ice with PE-conjugated streptavidin (1:100 dilution in 15 
FACS buffer) (BD Biosciences). After two final washes, the cells were fixed with phosphate-buffered saline 16 
(PBS) containing 1% paraformaldehyde, and the fluorescence intensity was measured on a flow cytometer 17 
(EPICS XL, Beckman Coulter or FACS Aria, BD Biosciences). 18 
 19 
Detection of BLV p24 protein in cells 20 
One day before infection, each cell line (1×105 cells) was seeded into 35 mm dishes with 14 mm2 21 
collagen-coated glass bottoms (Matsunami Garasu Kougyou). On the following day, cells were pre-22 
incubated for 1 h at 37°C in 5% CO2 with medium containing 10 µg/ml polybrene and then incubated with 23 
1 ml FLK-BLV culture supernatant containing 10 µg/ml polybrene for an additional 1 h. For fixing and 24 
permeabilizing cells, IntraPrep Permeabilization Reagent (Beckman Coulter) was used. After removing the 25 
virus and rinsing the cells with FACS buffer, cells were fixed with 100 µl of Reagent 1 from the kit for 15 26 
min at room temperature (RT). Then, the dishes were rinsed with FACS buffer again and blocked for 20 27 
min at RT with a 4% aqueous solution of Block Ace (DS Pharma Biomedical) diluted 1:4 with FACS buffer. 28 
After blocking, dishes were rinsed with FACS buffer, 50 µl of Reagent 2 from the kit was added, and cells 29 
were incubated for 5 min at RT to permeabilize the cell membranes. Then, 50 µl of mouse anti-BLV p24 30 
antibody (BLV3; 1:50 dilution in Reagent 2) (VMRD) was added (1:100 dilution, final), and dishes were 31 
incubated for an additional 15 min at RT. After rinsing with FACS buffer, cells were incubated for 15 min 32 




and then washed with FACS buffer. Fluorescence was observed after mounting with 200 µl of VeltaShield 1 
(Vector Laboratories) on an Olympus IX71 fluorescence microscope.  2 
 3 
Quantification of reverse-transcribed BLV cDNA 4 
One day before infection, each cell line (1×106 cells) was seeded onto 6 cm culture dishes. The next 5 
day, cells were pre-incubated for 1 h at 37°C in 5% CO2 in medium containing 10 µg/ml polybrene. After 6 
the cells were cooled on ice for 10 min, they were incubated with 1ml of FLK-BLV culture supernatant 7 
containing 10 µg/ml polybrene for 1 h on ice. After removing the virus, cells were immediately harvested, 8 
washed, counted, and stored as a pellet (0 h) or cultured in fresh culture medium containing 10% FBS for 9 
4–24 h at 37°C in 5% CO2. They were then detached from the culture dishes and washed twice with PBS. 10 
After counting the cell number, the cell pellet was stored at -80°C. Extrachromosomal DNA was extracted 11 
from cells using a previously described method [27]. Briefly, the cell pellet was thawed, suspended in Tris-12 
EDTA buffer containing RNaseA, and lysed with SDS. Chromosomal DNA was precipitated with cesium 13 
chloride, potassium acetate, and acetic acid. Extrachromosomal DNA in the supernatant fraction was bound 14 
to QIAprep Spin columns (Qiagen) and eluted with 20 µl of H20 after washing.  15 
The copy numbers of BLV cDNA were measured on the QuantStudio 3 real-time PCR system 16 
(Applied Biosystems) using SYBR premix Ex Taq II (Tli RNaseH plus) (TaKaRa Bio). Reactions were 17 
performed as recommended by the manufacturer. Because the DNA concentrations, as measured by 18 
NanoDrop, were below the accurate range of detection (3–12 ng/µl), 2 µl of DNA was used for each 19 
reaction without adjusting the concentration. For DNA standards, serial dilutions of pBLV913 [28] DNA 20 
were used. The PCR conditions were as follows: 40 cycles of denaturation (95°C for 15 s), followed by 21 
annealing and extension (64°C for 30 s). Data were acquired after heating the reactions to 84°C after the 22 
extension cycle. Because the melting temperature of the target product is higher than 85°C, data 23 
acquisition at 85°C reduces the non-specific signal. The following primers specific for the R/U5 region of 24 
BLV were used for amplification: Forward (nt 327-346), 5’-agggtggttctcggctgaga-3’ and Reverse (nt 511-25 
530), 5’-tgtttgccggtctctcctgg-3’. The results are shown as the number of copies of BLV cDNA per 104 26 
cells.  27 





Production of viral progeny by different BLV-infected cell lines 2 
To detect progeny virus, mouse NIH3T3 cells, which have a high capacity to bind BLV (see below), 3 
were used. NIH3T3 cells also bound to recombinant BLV gp51 protein tagged with 6×Histidine, which 4 
could be detected by flow cytometry using a monoclonal antibody against the histidine tag (Online 5 
Resource 1). BLV bound to the surface of NIH3T3 cells was detected by flow cytometry using a 6 
monoclonal antibody specific for BLV gp51, which is a surface subunit of the envelope glycoprotein. 7 
This was then detected using biotin-labeled anti-mouse IgG and PE-conjugated streptavidin. A linear 8 
correlation between the mean fluorescence intensity (MFI) of the cells and the amount of BLV was 9 
observed in a preliminary experiment conducted using serially diluted BLV (Online Resource 2).  10 
Eleven different mammalian cell lines that were infected with BLV and then cultured for 7 days were 11 
examined for viral production. Progeny virus in the culture supernatant was detected by flow cytometry 12 
after binding to NIH3T3 cells. The 11 cell lines could be divided into two groups: those that supported 13 
production of progeny virus (detectable by the NIH3T3 cell-binding assay) and those that did not. The 14 
former included bovine BT cells and MDBK cells, bat Tb1Lu cells, cat CC81 cells, and human HOS 15 
cells. The latter included bovine EBTr cells, mouse NIH3T3 cells and SC-1 cells, rat NRK cells, rabbit 16 
SIRC cells, and monkey COS7 cells (Fig. 1a). Herein, we refer the former group of cells as “progeny-17 
producing cells” and the latter as “non-producing cells”. 18 
To confirm the cells’ capacity to support the production of infectious progeny virus, we chose three 19 
progeny-producing cell lines (BT, MDBK, and CC81) and three non-producing cell lines (NIH3T3, 20 
COS7, and SIRC), and tested them in a syncytium formation assay using cat CC81 cells, which generate 21 
multinucleated cells when infected with BLV [25]. Typical multinucleated cells were observed when cat 22 
CC81 cells were inoculated with cell-free culture fluid from BLV-infected BT cells or CC81 cells (Fig. 23 
1b). Average numbers of syncytia per square were 5.5 and 4.0 for culture fluids from BLV-infected BT 24 
cells and CC81 cells (equal to 1.9×102 and 1.5×102 per dish), respectively. Culture fluid from FLK-BLV 25 
induced 34 syncytia per square when used at a 1:5 dilution. However, culture fluid from BLV-infected 26 
bovine MDBK cells did not induce syncytia in CC81 cells, despite their ability to produce progeny BLV 27 
in the NIH3T3-binding assay. NIH3T3, COS7, and SIRC cells did not make syncytia with CC81 cells.  28 
 29 
Viral attachment to the surface of different cell lines 30 
We next compared the efficiency of different BLV replication steps between progeny-producing and 31 
non-producing cell lines. The efficiency of BLV binding to the surface of 11 cell lines was analyzed by 32 




of cells incubated with (shaded) or without (non-shaded) BLV are shown in Figure 2. The capacity for 1 
virus production shown in Figure 1 is also listed to the left of the histograms in Figure 2. All 11 cell lines 2 
bound BLV but FLK-BLV cells did not bind BLV, probably due to receptor interference. NIH3T3 and SC-3 
1 cells, which are not derived from cattle, bound particularly high levels of virus, but did not produce 4 
progeny. Among the bovine cell lines, only BT cells showed an intermediate level of BLV binding; 5 
MDBK and EBTr cells showed a very low level of binding. Overall, the ability of progeny-producing and 6 
non-producing cells to bind virus did not significantly differ.  7 
 8 
Viral entry into different cell lines 9 
In subsequent experiments, the two cell lines that were confirmed to produce infectious progeny 10 
BLV (CC81 and BT) and three non-producing cell lines (NIH3T3, COS7, and SIRC) were examined 11 
further. For the non-producing cells, cells that showed different levels of BLV binding were selected.  12 
To examine viral entry, the five cell lines were infected with BLV for 1 h, and intracellular viral p24 13 
gag protein was visualized after fixation and permeabilization by staining with a mouse monoclonal 14 
antibody against BLV p24 and a FITC-labeled anti-mouse IgG (Fig. 3). Intracellular BLV p24 was 15 
observed in all five cell lines, mainly in the cytosol, and there was no difference in the localization pattern 16 
among the cell lines.  17 
 18 
Viral cDNA synthesis in different cell lines  19 
We next examined the efficiency of viral cDNA synthesis in the five cell lines. To measure reverse-20 
transcribed cDNA prior to integration, extrachromosomal DNA was extracted by the modified Hirt’s 21 
procedure [27] from cells that were incubated with BLV on ice to bind virus on their surface, and then 22 
incubated at 37°C for 4–24 h so that viral infection could occur. The number of BLV cDNA copies was 23 
measured by real-time PCR with a primer set for an early reverse transcript (Fig. 4). In the case of CC81 24 
and BT cells, both of which were progeny-producing, the amount of viral cDNA exceeded 600 copies/104 25 
cells at 4 h, and the levels remained at over 400 copies/104 cells at 24 h. However, non-producing 26 
NIH3T3 and COS7 cells harbored less than 200 copies/104 cells at the peak time point (4 h), and less than 27 






Here, we examined the early stages (i.e., attachment, entry, and reverse transcription) of the BLV 2 
replication cycle and found that the only difference between progeny-producing and non-producing cells 3 
was the efficiency of reverse transcription. 4 
Cell lines were divided into progeny-producing and non-producing groups; however, MDBK cells 5 
showed dual characteristics in that they appeared to produce progeny virus by the NIH3T3-binding assay, 6 
but it did not form syncytia on CC81 cells. To ascertain whether this unexpected character was specific to 7 
MDBK cells, we conducted further experiments on syncytium formation by Tb1Lu and HOS cells, which 8 
showed progeny-producing ability in the NIH3T3-binding assay, and confirmed that culture fluid from 9 
BLV-infected these cells could induce syncytium formation with CC81 cells (data not shown). In our 10 
procedure, the syncytium formation assay was more than 100-fold less sensitive than the NIH3T3 cell-11 
binding assay; thus, it is not clear whether the amount of progeny virus produced by MDBK cells was 12 
simply below the detection limit of our syncytium formation assay or whether MDBK cells do not produce 13 
infectious progeny. Further study is needed to characterize MDBK cells. 14 
BLV attached to all tested cell lines, although the amount of attached virus varied (Fig. 2). The bovine 15 
cells did not show a high level of BLV binding despite being a natural host; especially MDBK and EBTr 16 
cells showed very low binding. In a previous study, genetic variation of BLV was observed after its 17 
replication in sheep-derived FLK cells [29]. It is possible that the BLV used in this study had become 18 
adapted to sheep, and that a fresh field isolate of BLV from cow would have bound more bovine cells. 19 
Although no cellular receptor for BLV has been identified to date [30–32], our findings are consistent with 20 
those of a previous study, showing that an N-terminal region in the envelope glycoprotein that is 21 
homologous to the receptor-binding domain of the HTLV envelope binds to cell lines derived from various 22 
mammalian species [33]. 23 
Furthermore, BLV entered all five of the cell lines tested, and there was no observable difference in 24 
the localization of BLV p24 protein among the cells (Fig. 3), suggesting that BLV can penetrate into the 25 
cytoplasm of all these cell lines. To confirm the intracellular localization of p24, we tested whether 26 
surface protein was stained after fixation and permeabilization treatment. BLV gp51 protein on the BLV-27 
infected cells was detected clearly using a monoclonal antibody against gp51 without fixation and 28 
permeabilization treatment, but was not detected after the treatment as noted in the manufacturer’s 29 
instructions for the reagent (data not shown), suggesting that p24 protein stained with the antibodies are 30 
not one on the surface.  31 
Extrachromosomal DNA has been used to identify viral DNAs in infected cells because the fraction 32 




the viral reverse transcripts prior to integration, the modified Hirt’s procedure [27] was used to extract 1 
extrachromosomal DNA. The modified procedure can extract small DNAs in the linear form as well as in 2 
the circular form [27]. Primers were positioned in the 5’-long terminal repeat, which allows the detection 3 
of the early products of reverse transcription [35]. The amount of early viral cDNA transcripts in the 4 
extrachromosomal DNA clearly differed between BLV-producing and non-producing cell lines. To rule out 5 
viral cDNA contamination from the BLV-containing culture supernatant, cells incubated with BLV on ice 6 
but not cultured at 37°C were used as the first time-point (0 h). Relatively little viral cDNA was detected 7 
at 0 h in all of the cell lines tested (less than 5.5 copies/104 cells). Previous studies have shown that cells 8 
from various species can be infected with BLV and produce virus-derived protein; however, the reported 9 
efficiencies are not consistent [18–20]. Here, we observed low levels of reverse transcription in non-10 
producing cells, which is consistent with these results.  11 
In many cases, viral cellular tropism is determined by the expression of virus receptors. This work 12 
shows that BLV can bind a wide range of cells and that the ability of cells to produce BLV progeny is 13 
determined by factors operating either prior to or at the start of reverse transcription. Studies of primate 14 
lentiviruses and murine retroviruses suggest that several host restriction factors affect virus replication 15 
(reviewed in [36–39]). It is possible that such cellular factors are associated with replication of BLV as well. 16 
The findings reported here are not detailed enough to help identify the factors, but rather justify further 17 
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Figure Captions 1 
Fig. 1 Amount of progeny virus produced by BLV-infected cells 2 
a  BLV production measured in an NIH3T3 cell-binding assay. Progeny virus produced by BLV-infected 3 
cell lines derived from various mammalian species (shown on the left) was detected by flow cytometry 4 
after absorption to NIH3T3 cells, followed by staining with a mouse anti-gp51 antibody, a biotin-5 
labeled anti-mouse IgG antibody, and PE-labeled streptavidin. The mean fluorescence intensity of 6 
10,000 NIH3T3 cells was analyzed in each sample. FLK-BLV is a BLV-producing cell line used as a 7 
positive control. The control sample shows the background staining of antibodies and PE-labeled 8 
streptavidin in the absence of BLV. Three independent experiments for BT, MDBK, NIH3T3, SIRC, 9 
CC81, and COS7 cells, and two independent experiments for the other cell lines were done using 10 
EPICS XL or FACS Aria. All experiments yielded similar results. A representative result obtained 11 
using EPICS XL is shown. 12 
 13 
b Syncytia formation in CC81 cells by BLV produced from BT, CC81, and FLK-BLV cells. CC81 cells 14 
were cultured for 4 days with culture supernatant from BLV-infected cells. Multinucleated cells were 15 
observed after fixation and Giemsa staining. 16 
 17 
Fig. 2 Relative amounts of BLV attached to the cell surface 18 
Cell lines derived from various mammalian species (shown on the left) were incubated with culture 19 
supernatant from FLK-BLV cells, which contains infectious BLV virions. BLV attached to the cell 20 
surface was detected by flow cytometry using FACS Aria after staining with a mouse anti-gp51 21 
antibody, a biotin-labeled anti-mouse IgG antibody, and PE-labeled streptavidin. The mean 22 
fluorescence intensity of 10,000 cells was analyzed and the averages of three independent experiments 23 
are shown in the bar graphs. Unshaded graphs show the background binding of antibodies and PE-24 
labeled streptavidin in the absence of BLV. The bars show the standard errors of three independent 25 
experiments. For FLK-BLV cells, the result of one experiment is shown. The capacity of each cell line 26 
to maintain virus production is also shown.  27 
 28 
Fig. 3 Localization of BLV p24 capsid protein  29 
Cells were infected BLV for 1 h, and intracellular BLV p24 capsid protein was labeled with a mouse 30 
anti-BLV p24 antibody and FITC-labeled anti-mouse IgG after fixation and permeabilization of the 31 
cells. The FITC signal was observed by fluorescence microscopy (Olympus IX71) at 320× 32 





Fig. 4 Quantification of BLV cDNA  2 
Cells were incubated with culture supernatant from FLK-BLV cells, which contains infectious BLV, 3 
for 1 h on ice. After 0, 4, 12, and 24 h of incubation at 37°C, cells were counted and 4 
extrachromosomal DNA was extracted using the modified Hirt’s method [27]. The BLV cDNA copy 5 
number was measured by real-time PCR. The results obtained from BLV-producing cell lines are 6 
shown by solid symbols: CC81 (solid squares) and BT (solid diamonds) and those from non-7 
producing cell lines are shown by open symbols: NIH3T3 (open squares), COS7 (open diamonds) and 8 
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